


Supplementary Table 1: Characteristics of MDRD and AASK participants at baseline enrollment into their respective studies and at time of ESRD onset.

Characteristics at time of randomization	Strict Blood Pressure N=954 (432 from MDRD, 522 from AASK)	Usual Blood Pressure N=953 (408 from MDRD, 545 from AASK)	P-value
Mean age (y) (\pm SD)	53.0 \pm 11.7	53.3 \pm 11.3	0.57
Men N (%)	588 (61.1%)	573 (60.1%)	0.50
Blood pressure, systolic mm Hg(\pm SD)	142.7 \pm 24.0	141.7 \pm 22.2	0.35
Blood pressure, diastolic mm Hg (\pm SD)	89.5 \pm 14.8	88.7 \pm 14.2	0.23
Mean glomerular filtration rate (mL/min/1.73 m ²) (\pm SD)	40.4 \pm 14.6	40.2 \pm 14.8	0.77
Median glomerular filtration rate (mL/min/1.73 m ²) [IQR]	40.1 [28.8-51.7]	40.1 [27.3-52.6]	
Mean proteinuria (g/d) [IQR]	0.77 \pm 1.3	0.79 \pm 1.4	0.89
Median proteinuria (g/d) [IQR]	0.17 [0.05, 0.90]	0.16 [0.05, 0.85]	
Current smoker ¹	393 (41.2%)	364 (38.2%)	0.02
Angiotensin-converting enzyme inhibitor use	370 (38.8%)	357 (37.5%)	0.56

¹Data was missing in one person in MDRD strict BP arm



Supplementary Figure 1.



Supplementary Figure 1: Distribution of ESRD cases and death by BP study arm assignment in meta-analysis of AASK and MDRD.

Supplementary Figure 2

HR=0.88 [95% CI 0.78-1.0]



Supplementary Figure 2: Risk of (a) ESRD and (b) death during long-term extended follow-up of MDRD and AASK trial participants.